At a glance
- Originator Aventis
- Developer Aventis; Juvabis Therapeutics
- Class Aminoglycosides; Antibacterials; Small molecules
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Gram-negative infections
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for phase-I development in Gram-negative-infections(In volunteers) in Germany (IV, Infusion)
- 30 Sep 2020 Juvabis Therapeutics completes a phase I trial in Gram-negative infections (In volunteers) in Germany (NCT04105205)
- 26 Sep 2019 Juvabis Therapeutics plans a phase I trial for Apramycin in healthy volunteers in Germany (IV, Infusion) (NCT04105205)